UK Dementia Research Institute, Basic and Clinical Neuroscience, King's College London, London, UK
UK Dementia Research Institute, Care Research and Technology Centre, Imperial College London, London, UK.
BMJ Open. 2023 Aug 3;13(8):e072094. doi: 10.1136/bmjopen-2023-072094.
Digital biomarkers can provide a cost-effective, objective and robust measure for neurological disease progression, changes in care needs and the effect of interventions. Motor function, physiology and behaviour can provide informative measures of neurological conditions and neurodegenerative decline. New digital technologies present an opportunity to provide remote, high-frequency monitoring of patients from within their homes. The purpose of the living lab study is to develop novel digital biomarkers of functional impairment in those living with neurodegenerative disease (NDD) and neurological conditions.
The Living Lab study is a cross-sectional observational study of cognition and behaviour in people living with NDDs and other, non-degenerative neurological conditions. Patients (n≥25 for each patient group) with dementia, Parkinson's disease, amyotrophic lateral sclerosis, mild cognitive impairment, traumatic brain injury and stroke along with controls (n≥60) will be pragmatically recruited. Patients will carry out activities of daily living and functional assessments within the Living Lab. The Living Lab is an apartment-laboratory containing a functional kitchen, bathroom, bed and living area to provide a controlled environment to develop novel digital biomarkers. The Living Lab provides an important intermediary stage between the conventional laboratory and the home. Multiple passive environmental sensors, internet-enabled medical devices, wearables and electroencephalography (EEG) will be used to characterise functional impairments of NDDs and non-NDD conditions. We will also relate these digital technology measures to clinical and cognitive outcomes.
Ethical approvals have been granted by the Imperial College Research Ethics Committee (reference number: 21IC6992). Results from the study will be disseminated at conferences and within peer-reviewed journals.
数字生物标志物可以为神经疾病的进展、护理需求的变化以及干预措施的效果提供一种具有成本效益、客观和可靠的衡量标准。运动功能、生理学和行为可以为神经状况和神经退行性衰退提供有意义的衡量标准。新的数字技术为在患者家中提供远程、高频监测提供了机会。生活实验室研究的目的是开发用于检测患有神经退行性疾病(NDD)和其他非退行性神经疾病的患者的功能障碍的新型数字生物标志物。
生活实验室研究是一项对患有 NDD 和其他非退行性神经疾病的患者的认知和行为进行的横断面观察性研究。将对痴呆症、帕金森病、肌萎缩性侧索硬化症、轻度认知障碍、创伤性脑损伤和中风患者(每个患者组≥25 名)以及对照组(≥60 名)进行实用招募。患者将在生活实验室中进行日常生活活动和功能评估。生活实验室是一个包含功能厨房、浴室、床和起居区的公寓式实验室,为开发新型数字生物标志物提供了一个受控环境。生活实验室是常规实验室和家庭之间的一个重要中间阶段。将使用多个被动环境传感器、互联网医疗设备、可穿戴设备和脑电图(EEG)来描述 NDD 和非 NDD 疾病的功能障碍。我们还将这些数字技术措施与临床和认知结果联系起来。
帝国理工学院研究伦理委员会已批准该研究(参考号:21IC6992)。研究结果将在会议上和同行评议期刊上发表。